Daiichi Sankyo

This study is testing whether adding a newer targeted drug (trastuzumab deruxtecan) to an existing maintenance drug (bevacizumab) works better than the existing drug alone to keep ovarian cancer from returning. The trial involves 582 adults with advanced ovarian cancer who have j…

This study is testing an experimental drug called ifinatamab deruxtecan (I-DXd) for people whose small cell lung cancer has returned after initial treatment. It will compare I-DXd against standard treatments chosen by doctors to see which works better at shrinking tumors and help…

This is the first human trial testing a new cancer drug called DS5361b, both alone and combined with an existing immunotherapy drug (pembrolizumab). The study aims to find the safest dose and see if it helps control advanced solid tumors in people who have run out of standard tre…

This is the first human trial of an experimental drug called DS9051b for people with advanced adrenal gland cancer or metastatic prostate cancer that has stopped responding to standard hormone treatments. The main goal is to find a safe dose and understand the drug's side effects…

This is the first time a new cancer drug called ifinatamab deruxtecan (I-DXd) is being tested in people. The study aims to find a safe and effective dose for patients with advanced solid tumors that have not responded to standard treatments. Researchers will monitor participants …

This study aims to understand how well the drug trastuzumab deruxtecan works and what side effects patients experience in real-world medical settings in China. It will follow 800 adults with advanced breast cancer that has spread and is difficult to remove surgically. Researchers…

This early-stage study is testing the safety and initial effectiveness of combining two cancer drugs, valemetostat and a DXd antibody-drug conjugate, in people with advanced solid tumors. It will enroll about 210 adults with specific types of advanced breast, lung, or stomach can…

This trial is testing whether an experimental drug called R-DXd can help control advanced cancers that have spread and stopped responding to standard treatments. The study will enroll 200 adults with specific advanced cancers including ovarian, cervical, kidney, and bladder cance…

This is an early-stage trial testing the safety and initial effectiveness of combining two drugs, valemetostat and darolutamide, for men with metastatic castration-resistant prostate cancer (mCRPC). The study will enroll about 60 men whose cancer has spread and is no longer respo…

This study is testing an experimental drug called ifinatamab deruxtecan (I-DXd) for people with advanced esophageal cancer that has continued to grow despite receiving standard chemotherapy and immunotherapy. The main goal is to see if I-DXd helps patients live longer compared to…

This study is testing a new combination of drugs for people with extensive-stage small cell lung cancer who are starting their first treatment. The main goals are to find a safe dose and see if the combination can help control the cancer. The trial will enroll about 123 adults an…

This study is testing whether adding a new drug called valemetostat to a standard immunotherapy (pembrolizumab) works better than the standard drug alone for people with advanced non-small cell lung cancer. It is for adults who have not had prior treatment for their advanced canc…

This study is testing an experimental drug called ifinatamab deruxtecan (I-DXd) in people with advanced solid tumors that have returned or spread after standard treatments. It aims to see if the drug can shrink tumors and control the disease for various cancers, including endomet…

This large, late-stage trial is comparing new drug combinations against the current standard treatment for advanced stomach or gastroesophageal cancer that has a specific marker (HER2-positive). It aims to see if adding newer targeted drugs to chemotherapy can better control the …

This is the first human study testing a new cancer drug called DS-3939a in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial will enroll 540 participants to determine safe dosage levels and see if the drug helps control cancer growth. R…

This trial is testing whether a drug called quizartinib can help prevent a specific type of acute myeloid leukemia (AML) from coming back. It is for adults whose cancer is in remission after initial treatment but who have not had a stem cell transplant. The study will compare two…

This is the first study in humans testing a new cancer drug called DS3610a. It aims to find a safe and tolerable dose for people with advanced solid tumors that have stopped responding to standard treatments. The study will enroll about 70 participants to monitor side effects and…

This early-stage trial is testing a new under-the-skin injection version of a cancer drug called trastuzumab deruxtecan. It aims to see if this method is safe, tolerable, and effective for adults whose solid tumors have spread or returned after treatment. The study will first fin…

This study is testing whether adding a new drug called Dato-DXd to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for advanced lung cancer. It will involve 740 adults with a specific type of advanced non-small cell lung cancer who haven't had any p…

This study tests an existing cancer drug called T-DXd in people with advanced breast cancer that has low levels of a protein called HER2. It aims to see how well the drug controls the cancer and improves quality of life for up to 250 participants whose cancer has spread and canno…

This study is testing whether a newer, targeted drug called trastuzumab deruxtecan (T-DXd) works better than standard chemotherapy after surgery for certain types of endometrial cancer. It is for people whose cancer tests positive for a protein called HER2. The main goal is to se…

This study compares a new two-drug combination (trastuzumab deruxtecan plus pembrolizumab) against standard chemotherapy plus pembrolizumab for people with advanced non-small cell lung cancer that has spread and has specific tumor markers. It aims to see if the new combination ca…

This study allows patients with advanced or metastatic cancer who are benefiting from certain experimental drugs to continue receiving them after their original trial ends. It aims to provide continued treatment access while closely monitoring for any long-term side effects. The …

This is the first human trial testing an experimental drug called DS3790a for people with various blood cancers. The study aims to find safe doses and see if the drug, given alone or with other treatments, can help control these cancers. Researchers will enroll 420 adults with bl…

This large Phase 3 study is testing whether adding the drug quizartinib to standard chemotherapy helps adults newly diagnosed with a specific type of acute myeloid leukemia (AML) live longer. The trial will enroll 700 patients who test negative for a particular genetic marker (FL…

This study is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in people with advanced solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors and control the disease in people who have already tried at l…

This study is for people with advanced bladder cancer that has continued to grow despite receiving a specific prior combination treatment. It will compare a new drug combination (datopotamab deruxtecan plus a platinum chemotherapy) against a standard chemotherapy combination. The…

This study is testing a new drug called R-DXd for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to standard platinum-based chemotherapy. The drug is designed to target cancer cells specifically. The trial aims to find the be…

This study follows patients for up to 10 years to better understand the long-term risk of serious liver problems in people who took TURALIO for a rare joint tumor. Researchers will track 30 adults who developed specific liver test abnormalities while on the medication. The goal i…

This early-stage study aims to understand how a single dose of the drug quizartinib is processed by the body in people with severe liver impairment. It will compare 12 participants with poor liver function to healthy volunteers, measuring drug levels in the blood and checking for…